Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Magainin 2
Overview
Magainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells.
Mechanism of Action
Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens.
Research Summary & Key Findings
Early preclinical studies demonstrated activity against gram-positive and gram-negative bacteria, fungi, and protozoa in vitro and in animal infection models. Clinical development of magainin 2 itself was limited due to modest potency and susceptibility to proteolytic degradation. Derivatives such as pexiganan were subsequently developed to improve stability and therapeutic potential.
Clinical Status
Magainin 2 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Magainin 2"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Magainin 2"
Registered interventional and observational studies, including status and phase.
- PubChem: "Magainin 2"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Antimicrobial
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fus...
View detailsPexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic st...
View detailsOmiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring pep...
View detailsIseganan (IB-367)
InvestigationalIseganan is a 17-amino acid synthetic analog of protegrin, a naturally occurring antimicrobial peptide found in porcine ...
View detailsNo lawful pathway today
Magainin 2 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.